Project WAVE recruits first patient

RNS Number : 6173C
Inspiration Healthcare Group PLC
22 June 2021
 

 

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

 

 

Project WAVE recruits first patient

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that the first patient has been recruited at the Trevor Mann Baby Unit, Brighton & Sussex University Hospital (Royal Sussex) for Project WAVE, the newly developed respiratory device designed by Inspiration Healthcare for use in neonatal intensive care.  

Inspiration Healthcare acquired the technology for Project WAVE under a licence agreement in 2018 from the  University of California Los Angeles and has subsequently developed it further to produce a patented device which is non-invasive and designed to reduce intermittent hypoxia in the new born. The project was granted a patent by the U.S. Patent Office in March 2020.

Neil Campbell, Chief Executive Officer, commented: "This is really exciting news. The first patient to be recruited on the trial is a real milestone for us and we eagerly await to see how the trial progresses.  We continue to talk to other research groups about their interest and to refine the device as we develop our commercial strategy." 

 

Enquiries:

 

Inspiration Healthcare Group plc

Neil Campbell, Chief Executive Officer

Jon Ballard, Chief Financial Officer

Tel: 01455 840555

 

Nominated Adviser & Broker

Cenkos Securities plc

Mark Connelly

Stephen Keys

Tel: 0207 397 8900

 

Cadogan PR 

Alex Walters

alex.walters@cadoganpr.com

Tel: 07771 713608

 

About Inspiration Healthcare Group

 

www.inspirationhealthcaregroup.plc.uk

 

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in critical care & operating theatres. The Company provides high-quality, innovative products to patients around the world which help to improve patient outcomes, and it actively invests in innovative product opportunities and disruptive technologies.

 

The Group currently consists of three companies: Inspiration Healthcare Ltd, SLE Ltd and Viomedex Ltd and under these brands the Group sells neonatal intensive care and operating theatre equipment around the work through a network of distributors into over 75 countries.  Products range from highly sophisticated capital equipment through to single use disposables all that can help improve outcomes of extremely sick patients.

 

In the UK and Ireland the Group offers direct sales for most of its products supported by Technical Service offering on site and return to base repair and maintenance along with 24/7 emergency hire of equipment and long term lease arrangements for its own brand products.  The Group also acts as a distributor for 3rd party companies that wish to access the NHS using the Group's sales and service expertise and knowledge of the NHS

 

The Group invests in growth through Research and Development holding numerous patents on its technology and has strong links with academic Key Opinion Leaders around the world and supports clinical research in the field of neonatal intensive care.

 

Further information on Inspiration Healthcare Group plc can be seen at  www.inspirationhealthcaregroup.plc.uk  

 

 

 

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFITRVILFIL
UK 100

Latest directors dealings